אזילקט
teva israel ltd - rasagiline as mesylate - טבליה - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
אזילקט
teva pharmaceutical industries ltd, israel - rasagiline as mesylate - טבליה - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
אזילקט
teva pharmaceutical industries ltd, israel - rasagiline as mesylate - טבליה - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
רסג'ילין סנדוז 1 מג
novartis israel ltd - rasagiline as tartrate - טבליה - rasagiline as tartrate 1 mg - rasagiline
אזילקט
teva pharmaceutical industries ltd, israel - rasagiline as mesylate - טבליה - rasagiline as mesylate 1 mg - rasagiline
רסג'ילין – תרימה
trima israel pharmaceutical products maabarot ltd - rasagiline as mesylate - טבליה - rasagiline as mesylate 1 mg - rasagiline
ראסאג'ילין אינובמד
inovamed ltd - rasagiline as hemitartrate - טבליה - rasagiline as hemitartrate 1 mg - rasagiline
רז-אג'ילין 1 מג
raz pharmaceutics ltd, israel - rasagiline as tartrate - טבליה - rasagiline as tartrate 1 mg - rasagiline
לאייף 600
bayer israel ltd - hypericum perforatum - טבליות מצופות פילם - hypericum perforatum 612 mg - symptoms of mild to moderate depression. treatment is recommended for up to 12 weeks.
ספרייסל 100 מג
bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.